The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| MicardisPlus telmisartan;hydrochlorothiazide | Boehringer Ingelheim International GmbH | Hypertension | 🇪🇺 EU 2002-04-19 | Order → |
| Invanz ertapenem | Merck Sharp & Dohme B.V. | Community-Acquired Infections; Streptococcal Infections; Staphylococcal Infections; Gram-Negative Bacterial Infections; Surgical Wound Infection; Pneumonia, Bac | 🇪🇺 EU 2002-04-18 | Order → |
| Dynastat parecoxib | Pfizer Europe MA EEIG | Pain, Postoperative | 🇪🇺 EU 2002-03-22 | Order → |
| Rayzon parecoxib | Pharmacia Europe EEIG | Pain, Postoperative | 🇪🇺 EU 2002-03-22 | Order → |
| Xapit parecoxib | Pharmacia Europe EEIG | Pain, Postoperative | 🇪🇺 EU 2002-03-22 | Order → |
| Quixidar fondaparinux sodium | Glaxo Group Ltd. | Venous Thrombosis; Pulmonary Embolism; Myocardial Infarction; Angina, Unstable | 🇪🇺 EU 2002-03-21 | Order → |
| Arixtra fondaparinux sodium | Viatris Healthcare Limited | Venous Thrombosis; Pulmonary Embolism; Myocardial Infarction; Angina, Unstable | 🇪🇺 EU 2002-03-20 | Order → |
| Vfend voriconazole | Pfizer Europe MA EEIG | Candidiasis; Mycoses; Aspergillosis | 🇪🇺 EU 2002-03-19 | Order → |
| Dynepo epoetin delta | Shire Pharmaceutical Contracts Limited | Kidney Failure, Chronic; Anemia | 🇪🇺 EU 2002-03-18 | Order → |
| Kineret anakinra | Swedish Orphan Biovitrum AB (publ) | Arthritis, Rheumatoid; COVID-19 virus infection | 🇪🇺 EU 2002-03-08 | Order → |
| Lumigan bimatoprost | AbbVie Deutschland GmbH & Co. KG | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2002-03-08 | Order → |
| Trisenox arsenic trioxide | Teva B.V. | Leukemia, Promyelocytic, Acute | 🇪🇺 EU 2002-03-05 | Order → |
| Protopy tacrolimus | Astellas Pharma GmbH | Dermatitis, Atopic | 🇪🇺 EU 2002-02-28 | Order → |
| Protopic tacrolimus | LEO Pharma A/S | Dermatitis, Atopic | 🇪🇺 EU 2002-02-27 | Order → |
| Viread tenofovir disoproxil | Gilead Sciences Ireland UC | Hepatitis B, Chronic; HIV Infections | 🇪🇺 EU 2002-02-04 | Order → |
| Travatan travoprost | Novartis Europharm Limited | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2001-11-27 | Order → |
| Glivec imatinib | Novartis Europharm Limited | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Mye | 🇪🇺 EU 2001-11-07 | Order → |
| Foscan temoporfin | Biolitec Pharma Ltd | Head and Neck Neoplasms; Carcinoma, Squamous Cell | 🇪🇺 EU 2001-10-24 | Order → |
| Cancidas (previously Caspofungin MSD) caspofungin | Candidiasis; Aspergillosis | 🇪🇺 EU 2001-10-23 | Order → | |
| Fabrazyme agalsidase beta | Sanofi B.V. | Fabry Disease | 🇪🇺 EU 2001-08-03 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.